Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC

BackgroundDespite disappointing outcomes from immuno-monotherapy, studies reported that NSCLC patients with EGFR mutation may possibly benefit from combined immunotherapy. Whether the response to prior EGFR-TKI has association with the outcomes of subsequent immunotherapy remains unclear.Patients an...

Full description

Bibliographic Details
Main Authors: Sangtian Liu, Fengying Wu, Xuefei Li, Chao Zhao, Yijun Jia, Keyi Jia, Ruoshuang Han, Meng Qiao, Wei Li, Jia Yu, Fei Zhou, Anwen Xiong, Bin Chen, Jue Fan, Shengxiang Ren, Caicun Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
targeted therapy
immunotherapy
programmed cell death ligand-1
EGFR-tyrosine kinase inhibitors (EGFR-TKI)
epidermal growth factor receptor
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.639947/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.639947/full

Similar Items